SRZN SURROZEN INC

Surrozen to Present at The Stifel 2021 Virtual Healthcare Conference

Surrozen to Present at The Stifel 2021 Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Surrozen, Inc., (Nasdaq: SRZN), a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, today announced that Craig Parker, Chief Executive Officer, will present at the Stifel 2021 Virtual Healthcare Conference at 4:40 p.m. ET on Tuesday, November 16. Interested parties may access the live webcast via the Investors section of the Surrozen website at . A replay of the webcast will be archived on the website.

About Surrozen

Surrozen is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. Surrozen is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with potential application across multiple disease areas, including inflammatory bowel disease, hepatitis, eye diseases, hearing loss, lung and airway diseases, and certain neurological disorders. For more information, please visit .

Media Contact:

Ian Stone, Managing Director

CanaleComm

Tel.: (619) 518-3518

Email: 

Investor Contact:

Email: 



EN
05/11/2021

Underlying

SRZNSURROZEN INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SURROZEN INC

 PRESS RELEASE
Free
SRZN SURROZEN INC

Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus on severe eye diseases, today announced that on November 6, 2025, Surrozen granted inducement stock option awards covering an aggregate of 50,000 shares of Surrozen common stock to the newly appointed Chief Financial Officer, Andrew P. Maleki, as an inducement material to acceptance of ...

November 12, 2025 1 EN
 PRESS RELEASE
Free
SRZN SURROZEN INC

Surrozen Reports Third Quarter 2025 Financial Results and Provides Bus...

Surrozen Reports Third Quarter 2025 Financial Results and Provides Business Update SOUTH SAN FRANCISCO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, with a focus on severe eye diseases, today announced financial results for the third quarter ended September 30, 2025, and provided a business update. Business HighlightsSurrozen remains focused on its ophthalmology pipeline, leveraging its Wnt biology...

November 7, 2025 1 EN
 PRESS RELEASE
Free
SRZN SURROZEN INC

Surrozen to Present at Upcoming Healthcare Investor Conference

Surrozen to Present at Upcoming Healthcare Investor Conference SOUTH SAN FRANCISCO, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus on severe eye diseases, today announced that Company management will present at an upcoming healthcare investor conference. Guggenheim 2nd Annual Healthcare Innovation Conference on November 12, 2025Surrozen Fireside Chat at 6:30 AM Pacific Time/9:30 AM Eastern Time Interested parties may access the audio ...

November 5, 2025 1 EN
 PRESS RELEASE
Free
SRZN SURROZEN INC

Surrozen Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4...

Surrozen Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus on severe eye diseases, today announced that on September 2, 2025, Surrozen granted inducement stock option awards covering an aggregate of 45,710 shares of Surrozen common stock to four recently hired non-executive employees as an inducement material to their acceptance of employment...

September 4, 2025 1 EN
 PRESS RELEASE
Free
SRZN SURROZEN INC

Surrozen to Present at Upcoming Healthcare Investor Conference

Surrozen to Present at Upcoming Healthcare Investor Conference SOUTH SAN FRANCISCO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus on severe eye diseases, today announced that Company management will present at an upcoming healthcare investor conference. H.C. Wainwright 27th Annual Global Investment Conference on Wednesday, September 10, 2025 Surrozen presentation will be from 8:30 – 9:00 AM Pacific Time/11:30 –12N Eastern Ti...

September 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch